Healthcare
Celldex Therapeutics Inc(CLDX)
Live Price
Offline$33.41
+3.02% today
1Y Change
+53.68%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $2.25B
- Revenue Growth
- -78.6%
- EPS Growth
- -59.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Celldex Therapeutics Inc (CLDX) is a Healthcare stock with a market cap of $2.25B and listed on NASDAQ. The stock last traded around $33.41 and up 53.7% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -78.6%, EPS growth of -59.2%, a dividend yield of 0.0%. What stands out right now is revenue -78.6%, EPS -59.2%, free cash flow -33.8% with operating margin -19160.0% and ROIC -53.9%. Valuation already assumes a fairly strong business story at price/sales 1502.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CLDX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-78.6% vs +7.6% peer median
Operating Margin
Below sector median
-19160.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -78.6% and EPS is at -59.2%, with operating margin around -19160.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.4% | -5.8% | -3.6% |
2026 Feb 25, 2026 | -22.0% | -0.6% | -4.2% | +2.8% |
2025 Nov 10, 2025 | -14.8% | +7.5% | +14.7% | +23.9% |
Benchmark Edge
CLDX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLDX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLDX Max Drawdown
-24.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CLDX and SPY.
Company Overview
Celldex Therapeutics Inc
NASDAQ
Celldex Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted immunotherapies for cancer and other serious diseases. Its research platforms leverage novel antibody therapeutics, antibody-drug conjugates, and immune-activating agents designed to engage the patient's immune system and deliver precise cytotoxic activity. Key product candidates include barzolvolimab, an investigational monoclonal antibody targeting KIT for chronic spontaneous urticaria and other mast cell-mediated disorders; glembatumumab vedotin, an antibody-drug conjugate against glycoprotein NMB for certain breast and skin cancers; varlilumab, an agonist antibody targeting CD27 to enhance immune responses; CDX-301, a recombinant human Flt3 ligand to expand dendritic and immune cell populations; CDX-1140, an antibody targeting CD40 to activate antigen-presenting cells; and CDX-0159, part of the anti-KIT program. Celldex Therapeutics Inc. advances these programs through clinical trials in oncology, neurology, and inflammatory diseases, primarily serving patients in North America via collaborations with academic centers and industry partners. Founded in 1983 and headquartered in Hampton, New Jersey, it plays a vital role in the biotechnology sector by pioneering next-generation immunotherapies.
- Leadership
- Mr. Anthony S. Marucci M.B.A.
- Employees
- 186
- Street Address
- Perryville III Building, Suite 220 53 Frontage Road
- Mailing
- Hampton, NJ, 08827
- Region
- Hampton, NJ, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1502.7
- Price/Book
- 4.3
Growth
- Revenue
- -78.6%
- EPS
- -59.2%
- Free Cash Flow
- -33.8%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -19160.0%
- Net Margin
- -17253.3%
- ROE
- -41.7%
- ROIC
- -53.9%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 10.49
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.